Krystal Biotech (KRYS)
Commercializes VYJUVEK and develops redosable genetic medicines across multiple organ systems.
Something off on this page? Send us feedback.
Commercializes VYJUVEK, a topical, redosable gene therapy for dystrophic epidermolysis bullosa, while advancing engineered HSV-1 treatments for eye, lung, skin, and tumor diseases. Revenue remains concentrated in VYJUVEK, and manufacturing is anchored by two in-house facilities.
Commercializes VYJUVEK, a topical, redosable gene therapy for dystrophic epidermolysis bullosa, across the United States, Europe, and Japan. The treatment is approved in the United States, European Union, United Kingdom, and Japan, with direct launches in major markets and specialty distributors elsewhere.
Builds engineered HSV-1 vectors for noninvasive or minimally invasive delivery across skin, eye, lung, and tumor tissue. Clinical programs include eye drops KB803 and KB801, inhaled KB407 and KB408, topical KB111, and oncology candidate KB707; Jeune Aesthetics develops injectable skin-aging program KB304. Development and commercial production are supported by two in-house manufacturing facilities.
Revenue remains concentrated in VYJUVEK, while European access depends on country-level pricing and reimbursement and every other program remains investigational.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 14, 2026 | RBC Capital | Initiate | Rating: —Target: — | Target: $400 |
| Jul 13, 2026 | Jefferies | Reiterate | Rating: —Target: $371 | Target: $474 |
| Jun 16, 2026 | H.C. Wainwright | Target | Target: $310 | Target: $361 |
| May 5, 2026 | Evercore ISI | Target | Target: $206 | Target: $300 |
| Feb 18, 2026 | Chardan Capital | Reiterate | Rating: —Target: $216 | Target: $323 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $845.6M · Total debt $8.9M · Total assets $1.50B · Shareholders' equity $1.36B
- Revenue
- $119.2M
- Operating income
- $58.4M
- Net income
- $54.8M
No dividends on record.
| Institutions | ≈ 102.13% | 30.23M shares | |
|---|---|---|---|
| 441 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 4.89% | 1.45M shares | |
| 5 holders · as of Sep 4, 2026 | |||
| Strategic holders | 5.42% | 1.61M shares | |
| 1 holder · as of Feb 3, 2022 | |||
| Adds to | 112.44% | ||
29.60M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 112.44%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 14.93% | 4.42M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 14.13% | 4.18M | as of Jun 30, 2026 |
Avoro Capital Advisors LLCInstitution | 9.76% | 2.89M | as of Jun 30, 2026 |
BlackRock, Inc.Strategic | 5.42% | 1.61M | filed Feb 3, 2022 |
Vanguard Portfolio Management LLCInstitution | 5.32% | 1.57M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 4, 2026 | Krish S. Krishnan | director, 10 percent owner, officer: President and CEO | −25,000 | $359.32 |
| Sep 4, 2026 | Suma Krishnan | director, 10 percent owner, officer: President, R&D | −25,000 | $359.32 |
| Aug 14, 2026 | Dino A. Rossi | director | −25,000 | $329.12 |
| Jun 25, 2026 | John Charles Thomas | officer: EVP, General Counsel | −1,000 | $347.27 |
| Jun 4, 2026 | Krish S. Krishnan | director, 10 percent owner, officer: President and CEO | −25,000 | $308.12 |
- Abeona Therapeutics
Only FDA-approved DEB rival; autologous gene therapy vs VYJUVEK
- Vertex Pharmaceuticals
CF modulator franchise that defines the market KB407 must enter
- Arcturus Therapeutics
Direct KB407 rival: inhaled mRNA for Class I CF via LUNAR platform
- Beam Therapeutics
AATD base-editing challenger; BEAM-302 pivotal cohort planned H2 2026
- Wave Life Sciences
AATD RNA editing rival: WVE-006 Phase 1b/2a, first human RNA edit
- BridgeBio Pharma
10-K-named DEB rival via affiliate Phoenix Tissue Repair (PTR-01)
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Krystal Biotech | $341.93 | −2.55% | $10.34B | 44.0 | 40.2 | 23.5 | +24.1% |
| Abeona Therapeutics | $5.70 | −2.15% | $331.7M | — | — | 13.0 | +2,745.0% |
| Vertex Pharmaceuticals | $510.79 | −0.82% | $130.71B | 30.0 | 26.6 | 10.4 | +12.5% |
| Arcturus Therapeutics | $13.71 | −4.64% | $408.7M | — | — | 17.2 | −89.5% |
| Beam Therapeutics | $24.96 | −3.74% | $2.67B | — | — | 17.1 | −94.2% |
| Wave Life Sciences | $4.01 | −7.92% | $857.2M | — | — | 13.1 | −73.9% |
| BridgeBio Pharma | $66.16 | −4.43% | $13.56B | — | — | 19.6 | +120.4% |
| Median | 30.0 | 26.6 | 15.1 | −30.7% |